0102030405
Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).
2024-07-19
- Program：Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).
- Indication: Second-line treatment approved for indications such as cholangiocarcinoma (developing resistance or in patients with brain metastases).
- Status：PCC
- Collaboration Opportunity:Equity financing, cooperative development, product transfer, etc.
- Highlights：
- Brain-penetrant resistant mutant FGFR2/3 inhibitors, suitable for treating brain metastases and brain cancer.
- Recently confirmed PCC molecules exhibit good inhibitory activity against resistant mutant forms of FGFR 2 and 3, with excellent brain penetration and in vivo efficacy. They pose no risk of hERG or CYPs inhibition, are well-tolerated, and have demonstrated good safety with no observed issues.